Hereditary common cancers: molecular and clinical genetics

Area of Science:

• Genetics and Molecular Biology
• Oncology
• Medical Genetics

Background:

• Hereditary cancers account for 5-10% of human tumors, often exhibiting rapid development.
• Genetic alterations in hereditary cancers occur over generations, contrasting with sporadic tumors.
• Cancer susceptibility genes are categorized as 'gatekeepers' (e.g., RB1, ki-ras) and 'caretakers' (e.g., BRCA1, hMLH1, hMSH2).

Purpose of the Study:

• To review the functional roles and structural features of genes implicated in common hereditary cancers.
• To highlight the importance of genetic testing and risk assessment for individuals predisposed to inherited cancer syndromes.
• To discuss current methods for assessing cancer risk based on specific gene mutations.

Main Methods:

• Review of scientific literature on hereditary cancer genes and their associated syndromes.
• Analysis of gene classifications ('gatekeepers' and 'caretakers') and their roles in tumorigenesis.
• Discussion of diagnostic approaches, including family history construction and genetic counseling.

Main Results:

• Identification of key genes associated with specific hereditary cancers: BRCA1/BRCA2 (breast/ovarian), hMLH1/hMSH2 (colorectal), APC (polyposis), RET (thyroid), p53 (Li-Fraumeni), p16 (melanoma), RB1 (retinoblastoma).
• Emphasis on the critical role of detailed three-generation family pedigrees in risk assessment.
• Established genetic tests for BRCA1/2, hMLH1/MSH2, APC, RET, p53, p16, and RB1 are valuable for risk stratification.

Conclusions:

• Accurate family history and genetic counseling are essential first steps in identifying individuals at high risk for hereditary cancers.
• Current genetic testing methods provide effective risk assessment for several major inherited cancer syndromes.
• Advancements in diagnostic testing promise more precise risk evaluation for asymptomatic individuals in the future.